Abstract
Objective
Glucose metabolism has not been investigated in human (in vivo) keloids. In the present study, we performed positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose (FDG) to examine glucose metabolism in keloids.
Materials and Methods
Five patients (2 men and 3 women) with typical keloids having a thickness of more than 5 mm were studied. HEADTOME-IV SET-1400W-10 (Shimadzu, Tokyo, Japan) was employed for PET studies. Transmission scanning was performed on each patient. After fasting for more than 4 hours, the patients were injected intravenously with FDG 185–370 (MBq) following each transmission scan. Emission scans were performed 40–55 min after injection. For quantitative evaluation, the regions of interest (Circles ROIs: 6 mm in diameter) were placed on all the keloid lesions and surrounding tissues, and then their standardized uptake value (SUV = the tissue concentration/the activity injected per body weight) was calculated.
Results
FDG was defined as showing the accumulation in keloids when its uptake was relatively higher in the keloid than that in the surrounding tissue. The SUV of the keloids ranged from 1.0 to 2.74, with a mean of 1.79.
Conclusion
FDG-PET was performed in 5 patients with keloids and low-grade accumulation of FDG was observed in all lesions. This indicated that glucose metabolism was accelerated in keloids.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Murray JC. Keloids and hypertrophic scars.Clin Dermatol 1994;12:27–37.
Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation.Mol Med Today 1998; 4: 19–24.
Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophie scars and keloids: a review.Plast Reconstr Surg 1999; 104: 1435–1458.
Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology.Ann Nucl Med 2001; 15: 471–486.
Schirmer M, Calamia KT, Wenger M, Klauser A, Salvarani C, Moncayo R.18F-fluorodeoxyglucose-positron emission tomography: a new explorative perspective.Exp Gerontol 2003; 38: 463–470.
Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET.J Med Invest 2004; 51:14–19.
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake.J Nucl Med 1994; 35: 104–112.
Ueda K, Furuya E, Yasuda Y, Oba S, Tajima S. Keloids have continuous high metabolic activity.Plast Reconstr Surg 1999; 104: 694–698.
Shetlar MR, Dobrkovsky M, Linares H, Villarante R, Shetlar CL, Larson DL. The hypertrophie scar. Glycoprotein and collagen components of burn scars.Proc Soc Exp Biol Med 1971; 138:298–300.
Kischer CW, Hendrix MJ. Fibronectin (FN) in hypertrophic scars and keloids.Cell Tissue Res 1983; 231: 29–37.
Kischer CW, Wagner HN Jr, Pindur J, Holubec H, Jones M, Ulreich JB, et al. Increased fibronectin production by cell lines from hypertrophie scar and keloid.Connect Tissue Res 1989; 23: 279–288.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ozawa, T., Okamura, T., Harada, T. et al. Accumulation of glucose in keloids with FDG-PET. Ann Nucl Med 20, 41–44 (2006). https://doi.org/10.1007/BF02985589
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02985589